---
type: Person
title: George Korch
description: Person appearing in 12 documents.
tags:
  - person
  - hhs
organization: hhs
document_count: 12
first_seen: "2010-01-18T07:52:00"
last_seen: "2010-01-31T21:37:00"
aliases:
  - George ( Korch
  - George Korch
sources:
  - { id: reading_room, resource: /sources/reading-room.md, title: Reading Room Production, author: "process:senate-hsgac-release" }
generated: { by: randpaul-corpus-pipeline/1.0, at: "2026-08-01T12:42:27Z" }
status: stable
---

Appears in the COVID-19 subpoena corpus.

# Activity

- **Documents:** 12 (sent/authored 6, received 8)
- **Active:** 2010-01-18 to 2010-01-31
- **Organization:** [hhs](/organizations/hhs.md)
- **Appears as:** `George ( Korch`, `George Korch`

# Correspondents

| Person | Messages | First | Last |
|---|---:|---|---|
| [Anthony S. Fauci](/people/anthony-s-fauci.md) | 7 | 2010-01-18 | 2010-01-30 |
| [Robin Robinson](/people/robin-robinson.md) | 4 | 2010-01-18 | 2010-01-30 |
| [Ezekiel Emanuel](/people/ezekiel-emanuel.md) | 2 | 2010-01-30 | 2010-01-30 |
| [Jesse Goodman](/people/jesse-goodman.md) | 2 | 2010-01-19 | 2010-01-19 |
| [Nicole Lurie](/people/nicole-lurie.md) | 2 | 2010-01-30 | 2010-01-31 |
| [Thomas Frieden](/people/thomas-frieden.md) | 2 | 2010-01-19 | 2010-01-19 |
| Anthony | 1 | 2010-01-30 | 2010-01-30 |
| Borio | 1 | 2010-01-30 | 2010-01-30 |
| Commissioner FDA | 1 | 2010-01-19 | 2010-01-19 |
| Daniel M Sosin | 1 | 2010-01-19 | 2010-01-19 |
| [Elizabeth A Bafford](/people/elizabeth-a-bafford.md) | 1 | 2010-01-27 | 2010-01-27 |
| Emanuel | 1 | 2010-01-30 | 2010-01-30 |
| Ezekiel | 1 | 2010-01-30 | 2010-01-30 |
| Gerald Parker | 1 | 2010-01-19 | 2010-01-19 |
| Luciana L | 1 | 2010-01-30 | 2010-01-30 |

# Topics

* [Intelligence community assessments](/topics/intelligence-community.md) - 6 documents
* [Vaccines](/topics/vaccines.md) - 4 documents
* [Awards, honoraria and recognition](/topics/awards-honoraria.md) - 1 documents
* [Biosafety and biosecurity](/topics/biosafety.md) - 1 documents
* [Congressional oversight](/topics/congressional-oversight.md) - 1 documents
* [Testing and surveillance](/topics/testing-surveillance.md) - 1 documents
* [Therapeutics and treatments](/topics/treatments.md) - 1 documents

# Statement timeline

What this person is recorded saying, in date order, quoted verbatim with page citations.

* **2010-01-30** ([intelligence_community](/topics/intelligence-community.md), asserts): "There are still important conversations to continue with our commercial partners." [^reading_room]
* **2010-01-30** ([intelligence_community](/topics/intelligence-community.md), asserts): "She pointed out that the industry itself has recently struggled with producing approved medical products for more highly valued commercial products." [^reading_room]
* **2010-01-30** ([vaccines](/topics/vaccines.md), asserts): "Merck started by reminding folks that they had in fact bid on the contract award for the cell culture derived smallpox vaccine, but had not been successful." [^reading_room]
* **2010-01-30** ([vaccines](/topics/vaccines.md), asserts): "One concrete example of how better understanding of a path to approval would affected a company's effectiveness in producing countermeasures was given by Novartis regarding use of an adjuvant to increase immunogenicity of a vaccine." [^reading_room]
* **2010-01-30** ([vaccines](/topics/vaccines.md), asserts): "In Europe, this pathway to use of adjuvant through their regulatory agency permitted the use of adjuvants in influenza vaccine, so what is the reason that the U.S. cannot seem to provide a reasonable pathway to accomplish a similar allowance ?" [^reading_room]
* **2010-01-30** ([vaccines](/topics/vaccines.md), acknowledges): "Liability It was noted by Merck that adequate liability is afforded to the industry on childhood vaccines (National Childhood Vaccine Injury Act), but that similar liability protections are not provided for adult vaccines." [^reading_room]
* **2010-01-30** ([intelligence_community](/topics/intelligence-community.md), asserts): "There are still important conversations to continue with our commercial partners." [^reading_room]

# Sources

[^reading_room]: [reading_room](/sources/reading-room.md)